Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      

This page is updated frequently with new Vaccine-related patent applications.




Date/App# patent app List of recent Vaccine-related patents
06/16/16
20160169888 
 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines patent thumbnailProteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey


06/16/16
20160166768 
 Apparatus and methods for self-administration of vaccines and other medicaments patent thumbnailApparatus and methods for self-administration of vaccines and other medicaments
A medicament delivery device includes a housing, a medicament container disposed within the housing, an activation mechanism, a cover and an electronic circuit system. The activation mechanism includes an energy storage member configured to produce a force to deliver the dose of a medicament and/or vaccine.
Kaleo, Inc.


06/16/16
20160166711 
 Rabies vaccine patent thumbnailRabies vaccine
Furthermore it also discloses the use of the mrna sequence or the composition comprising a plurality of mrna sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. For use in the prophylaxis or treatment of rabies virus infections.

06/16/16
20160166697 
 Method of treating cancer patent thumbnailMethod of treating cancer
The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or nkt agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent.
Intensity Therapeutics, Inc.


06/16/16
20160166686 
 Mini-intronic plasmid dna vaccines in combination with lag3 blockade patent thumbnailMini-intronic plasmid dna vaccines in combination with lag3 blockade
It is disclosed herein that (a) an anti-tumor dna vaccine delivered using a mip dna vector is a less effective tumor treatment than the corresponding anti-tumor dna vaccine delivered using a conventional pdna vector, despite the mip dna vector eliciting a higher frequency of antigen-specific cd8+ t cells; and (b) tumor infiltrating cd8+ t cells in animals immunized with the mip dna vector express higher levels of the immune checkpoint protein lag-3 than animals immunized with a conventional pdna vector, while the expression levels of other immune checkpoint proteins was the same for both groups. Based on these findings, improved methods and compositions for administering dna vaccines are disclosed.
Wisconsin Alumni Research Foundation


06/16/16
20160166681 
 Toll-like receptor agonists patent thumbnailToll-like receptor agonists
Compounds described herein can be used for therapeutic purposes. The compounds can be tlr agonists, such as tlr7 or tlr8 agonists.

06/16/16
20160166674 
 Vaccines for serogroup x meningococcus patent thumbnailVaccines for serogroup x meningococcus
A method for immunising a subject against serogroup x meningococcus by administering a vaccine comprising one, two or all three of: (i) a meningococcal fhbp antigen; (ii) a meningococcal nhba antigen; and/or (iii) a meningococcal nada antigen. The vaccine may also include meningococcal outer membrane vesicles..
Institut Pasteur


06/16/16
20160166673 
 Staphylococcus aureus proteins and nucleic acids patent thumbnailStaphylococcus aureus proteins and nucleic acids
The invention provides proteins from staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics..
Glaxosmithkline Biologicals Sa


06/16/16
20160166670 
 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections patent thumbnailCompositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc


06/16/16
20160166663 
 Vaccine formulations that induce a th2 immune response patent thumbnailVaccine formulations that induce a th2 immune response
The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.


06/16/16
20160166661 

Antibody-mediated anti-tumor activity induced by reishi mushroom polysaccharides


Immunogenic compositions, cancer vaccines and methods for treating cancer comprising fms, the fucose-enriched polysaccharide fraction from reishi f3, are provided. Compositions comprise fucose-enriched reishi polysaccharide fraction (fms) mw=˜35 kda, wherein the fms is isolated by size-exclusion chromatography from reishi f3, and the fms comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-α-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain immunogenic compositions comprising glycolipid adjuvants are provided.
Academia Sinica


06/09/16
20160159864 

Complexes of cytomegalovirus proteins


This disclosure provides an isolated human cytomegalovirus (hcmv) membrane protein complex, wherein said complex comprises gh, gl and at least one more hcmv glycoprotein. In some embodiments the complex consists of gh, gl and go.
Novartis Ag


06/09/16
20160158351 

Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants


Disclosed herein are pharmaceutical compositions comprising plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range plasmodium and analogues of α-galactosylceramide (α-galcer), a ligand for natural killer t (nkt) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria.
The Rockefeller University


06/09/16
20160158344 

Methods and compositions of protein antigens for the diagnosis and treatment of herpes simplex viruses type 1 and 2


Contemplated compositions, devices, and methods are drawn to various antigens from herpes simplex virus type 1 (hsv-1) and herpes simplex virus type 2 (hsv-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter..
Immport Therapeutics, Inc.


06/09/16
20160158343 

Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors


Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.. .
Albert Einstein College Of Medicine, Inc.


06/09/16
20160158342 

Vaccines for diseases caused by viruses of the family of reoviridae


The invention relates to methods for producing a propagation-competent strain of a mutant reoviridae virus, and to a propagation-competent strain of a mutant reoviridae virus that is obtainable by a method of the invention. The invention further relates to a propagation-competent strain of a mutant reoviridae virus, comprising a deletion of a genetic region that is relevant for propagation of the virus, and to a vaccine, comprising a propagation-competent strain of a mutant reoviridae virus..
Stichting Dienst Landbouwkundig Onderzoek


06/09/16
20160158340 

Influenza vaccines containing hemagglutinin and matrix proteins


An immunological composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in call culture rather than eggs.
Seqirus Uk Ltd.


06/09/16
20160158336 

Attenuated mannheimia haemolytica vaccines and methods of making and use


The present invention provides attenuated m. Haemolytica strains that elicit an immune response in animals against m.

06/09/16
20160158331 

Compositions and methods for treatment of non-hodgkins lymphoma


The present invention provides recombinant peptides comprising a b cell receptor (bcr) or a fragment thereof, nucleotide molecules encoding same, and vaccines and vectors comprising same; and methods of treating, inducing an immune response against, inducing a regression of, and suppressing a formation of a lymphoma, comprising administering same. The present invention also provides methods of inducing a humoral immune response in an animal against an antigen, comprising administering to the animal a fusion peptide comprising an llo protein or fragment thereof fused to the antigen..
The Trustees Of The University Of Pennsylvania


06/09/16
20160158329 

Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis


Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising one or more leishmania antigens as well as polynucleotides encoding such polypeptides..
Infectious Disease Research Institute


06/09/16
20160158327 

Genetically modified babesia parasites expressing protective tick antigens and uses thereof


The present invention relates to methods for stable transfection of babesia parasites, and for vaccines conferring immunity against parasitic arthropods.. .
The United States Of America As Represented By The Secretary Of Agriculture


06/02/16
20160153992 

Mutated parvovirus structural proteins as vaccines


The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one b-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.. .
Medigene Ag


06/02/16
20160153986 

Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines


The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey


06/02/16
20160152956 

Method for selecting a permissive cell line for replicating avian viruses


The present invention relates to a method for obtaining an untransformed avian cell line enabling in vitro avian virus replication. Said method includes the following steps: a) culturing avian embryonic stem cells in the presence of a stroma for at least 3 days; b) culturing for at least 2 days in a medium having a low serum concentration; c) culturing for at least 2 days in a medium having a low serum concentration containing 1 to 10 mm of hexamethyleme bisacetamide (hmba); d) culturing for at least 10 days in a medium having a low serum concentration; and e) culturing or freezing an avian cell line enabling avian virus replication.
Institut National De La Recherche Agronomique


06/02/16
20160152666 

Recombinant viral vectors


The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative


06/02/16
20160151483 

Beta-glycolipids for use as adjuvants


The present invention relates to beta-glycolipid derivatives, their preparation and use as adjuvants in vaccines, as being suitable for being co-administered with antigens for vaccine prophylaxis and therapy. In certain embodiments, the beta-glycol-lipid derivatives of the invention also in their salified or complex form, are suitable for being co-administered with antigens for both therapeutic and prophylactic purposes or for vaccine prophylaxis and therapy..
Consiglio Nazionale Delle Ricerche


06/02/16
20160151482 

Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery


The present invention relates to mesoporous alum nanoparticles which can be used as a universal platform for antigen adsorption, presentation and delivery to provide immune compositions, including vaccines and to generate an immune response (preferably, both humoral and cell mediated immune response), preferably a heightened immune response to the presentation of one or more antigens to a patient or subject.. .
Sandia Corporation


06/02/16
20160151480 

Universal influenza vaccine


The present invention includes an isolated antigen against influenza a and a method of making the same that includes an ectodomain of influenza a matrix protein 2 (m2e) and a stem region of an influenza a hemagglutinin 2 (ha2) protein and an adjuvant. The invention further includes formulating the antigen into an isolated immune response stimulating fusion protein and/or a vaccine..
Texas Tech University System


06/02/16
20160151474 

Vaccination in elderly patients


The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag


06/02/16
20160151473 

Vaccines using high-dose cytokines


The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response..
Sunnybrook And Women's College Health Sciences Center


05/26/16
20160146811 

Ompa and asp14 in vaccine compositions and as diagnostic targets


Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University


05/26/16
20160145320 

Broad-spectrum monoclonal antibody recognizing ha1 domain of hemagglutinin of influenza virus


The invention relates to antibodies recognizing epitopes on ha1 domain of hemagglutinin (ha) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to ha1 domain of different ha subtypes and specifically bind to ha1 domain of hemagglutinin (ha) protein of h1 subtype (including seasonal h1n1 and 2009 pandemic h1n1) and h5 subtype of influenza viruses.
Xiamen University


05/26/16
20160145255 

Non-nucleoside reverse transcriptase inhibitors


Are hiv reverse transcriptase inhibitors, wherein r1, r2, re, l, m and z are defined herein. The compounds of formula i and their pharmaceutically acceptable salts are useful in the inhibition of hiv reverse transcriptase, the prophylaxis and treatment of infection by hiv and in the prophylaxis, delay in the onset or progression, and treatment of aids.

05/26/16
20160144023 

Dry solid aluminum adjuvant-containing vaccines and related methods thereof


Described herein are dry vaccine compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry vaccine can be readily reconstituted to form a stable liquid vaccine without significant loss of activity.. .
Board Of Regents, The University Of Texas System


05/19/16
20160137987 

Recombinant influenza viruses for vaccines and gene therapy


The invention provides compositions and methods useful to prepare segmented, negative strand rna viruses, e.g., orthomyxoviruses such as influenza a viruses, entirely from cloned cdnas and in the absence of helper virus.. .
Wisconsin Alumni Research Foundation


05/19/16
20160136285 

An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria


The subject of the present invention is an isolated antigen being an immunogenic form of the common enterobacterial antigen (eca) of gram-negative bacteria of the family enterobacteriaceae: eca combined with lipopolysaccharide (ecalps); a glycoconjugate of inactivated form of this antigen with a protein, as well as compositions and vaccines containing such an antigen/glycoconjugate designed for the prevention and treatment infections caused by gram-negative bacteria.. .
Wroclawskie Centrum Badan Eit+ Sp. Z O.o.


05/19/16
20160136269 

Composition and treating cancer


Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (il), and at least one colony stimulating factor (csf), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same..
Oncbiomune, Inc.


05/19/16
20160136266 

Vaccine system for vaccine adjuvant


The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced th1 response. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions.
Vaxform Llc


05/19/16
20160136265 

Pharmaceutical composition for viral immunotherapy and uses thereof


The present disclosure relates to a method of overcoming host immune tolerance in a subject having chronic hepatitis b virus (hbv) infection, comprising administering to the subject an immunomodulatory agent and a recombinant hbv vaccine, such that the immune tolerance of the chronic hbv infection in the subject is overcome. Moreover, the present disclosure relates to a method of treating chronic hbv infection in a subject in need thereof, comprising administering to the subject a first anti-viral agent, an immunomodulatory agent and a recombinant hepatitis b vaccine, such that the hbv infection in the subject is treated..
Fudan University


05/19/16
20160136264 

Hepatitis b vaccine


Disclosed is a composition comprising: i) hbsag, a fragment thereof, a variant thereof, or the mixture of at least two of them, ii) hbcag1-x, a fragment thereof, a variant of the antigen or the antigen fragment, or the mixture of at least two of them, wherein x is an integer of from 149 to 183, iii) cpg-odn, 21 bases long, which is a phosphorothioate oligonucleotide and includes two or more copies of 5′-ntcgtt-3′ motifs. The use of the composition in the treatment of hbv-infection and hbv-induced diseases, and the therapy methods of hbv-infection and hbv-induced diseases are also disclosed..
Jiangsu Theravac Bio-pharmaceutical Co., Ltd.


05/19/16
20160136262 

Influenza virus vaccines and uses thereof


Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin ha1 domain that comprises an ha1 n-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the ha1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an ha1 c-terminal stem segment, comprising the amino acids from position y to and including the c-terminal amino acid of the ha1 domain; and (b) an influenza hemagglutinin ha2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between ha1 and ha2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza ha.. .
Crucell Holland B.v.


05/19/16
20160136261 

Live attenuated vaccines for influenza viruses


The subject invention pertains to attenuated influenza viruses, and related vaccines and methods, comprising a genetically modified viral genome. The genetically modified viral genome comprises a disruption in the non-structural (ns1) coding segment and one or more base substitution in the matrix membrane protein coding segment.
The University Of Hong Kong


05/19/16
20160136260 

Attenuated influenza vaccines and uses thereof


Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses.. .
University Of Rochester


05/19/16
20160136257 

Protein matrix vaccines and related methods of making and administering such vaccines


The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.. .
President And Fellows Of Harvard College


05/19/16
20160136256 

Polysaccharide-protein conjugate vaccines


Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


05/19/16
20160136255 

Vaccination with recombinant mycobacterium tuberculosis pknd attenuates bacterial dissemination to the brain


Vaccines comprising mycobacterium tuberculosis (m. Tuberculosis) pknd sensor polypeptides, compositions, kits, and methods of use for treating central nervous system tuberculosis are disclosed.
The Johns Hopkins University


05/19/16
20160136253 

Vaccines against pregnancy-associated malaria


The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the n-terminal portion of the var2csa protein of different parasitic families or lines of plasmodium falciparum, and to their use in the prevention of pregnancy-associated malaria. The invention also relates to immunogenic compositions and to vaccines useful for preventing malaria in pregnant women..
Institut De Recherche Pour Le DÉvelopment (ird)


05/19/16
20160136250 

Hydrophobic preparations


The present invention relates to preparations of substances in hydrophobic solvents in which they would not normally be soluble and to processes for obtaining these preparations. In particular, the invention relates to preparations of hydrophilic species in hydrophobic solvents such as oils.
Vaxcine Ltd.


05/12/16
20160132631 

Bioinformatic processes for determination of peptide binding


This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes..
Iogenetics, Llc


05/12/16
20160130562 

Attenuated african swine fever virus vaccine based in the deletion of mgf genes


African swine fever virus (asfv) is the etiological agent of a contagious and often lethal viral disease of domestic pigs. Control of asf has been hampered by the unavailability of vaccines.
The University Of Connecticut


05/12/16
20160130308 

Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof


Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of herpes virus antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provide herein are methods for generating an immune response against herpes virus using the vaccines that are provided..
The Thustees Of The University Of Pennsylvania


05/12/16
20160129104 

Hand, foot, and mouth vaccines and methods of manufacture and use thereof


The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.. .
Takeda Vaccines, Inc.


05/12/16
20160129103 

Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof


The present invention relates to infectious dna clones, infectious chimeric dna clones of porcine circovirus (pcv), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (pmws) caused by pcv2. The new chimeric infectious dna clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic pcv1 in which the immunogenic orf gene of the pathogenic pcv2 replaces a gene of the nonpathogenic pcv1, preferably in the same position.
Virginia Tech Intellectual Properties, Inc.


05/12/16
20160129102 

Compositions and methods for administration of vaccines against dengue virus


Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction.
Takeda Vaccines, Inc.


05/12/16
20160129098 

Targeting dna vaccines to b cells as primary antigen presenting cells


It is disclosed herein that b cells, not dendritic cells or myeloid-derived populations, are primary human antigen presenting cells for plasmid dna. Based on this finding, improved methods and compositions for administering dna vaccines are disclosed.
Wisconsin Alumni Research Foundation


05/12/16
20160129097 

Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit


The present invention provides methods for preparing and administering a tumor vaccine. The processes include resecting tumors and isolating tumor cells, followed by treatment with ultraviolet radiation to activate the tumor cells.

05/05/16
20160125129 

Predicting immunogenicity of t cell epitopes


The present invention relates to methods for predicting t cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not.
Trom


05/05/16
20160122412 

Composition comprised of antigen linked to a tnf superfamily ligand


The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of tnf superfamily (tnfsf) ligands. The tnfsfs serve as vaccine adjuvants for increasing the immune response to the antigens.

05/05/16
20160122398 

Recombinant rsv antigens


This disclosure provides recombinant respiratory syncytial virus (rsv) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of rsv infection.. .
Glaxosmithkline Biologicals, S.a.


05/05/16
20160122396 

Therapeutic hpv16 vaccines


Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against hpv16.. .
Crucell Holland B.v.


05/05/16
20160122378 

Method for producing beta-hematin crystal comprising step of heating


This invention provides a method of preparing a β-hematin crystal comprising a step of heating, the β-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the β-hematin crystal. The β-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 μm, and it exhibits main peaks characteristics for angles of diffraction (2θ) of 7.4°, 12.2°, 21.6°, and 24.1° in an x-ray diffraction pattern obtained by powder x-ray diffractometry with cu—kα rays (with each peak including a plus-minus 0.2° diffraction angle)..
Nippon Zenyaku Kogyo Co., Ltd.


05/05/16
20160120982 

Vaccine stabilizer


Wherein r1, r2, and r3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine n-oxide may be trimethylamine-n-oxide, (ch3)3no.

05/05/16
20160120975 

Fish vaccine


A composition comprising a translocation sequence derived from a fish pathogen and a heterologous payload coupled to the translocation sequence is provided. The composition is able to translocate across the plasma membrane of a eukaryotic cell, for example a fish cell, and thus stimulate an immune response.
The University Court Of The University Of Aberdeen


05/05/16
20160120973 

Attenuated swine influenza vaccines and methods of making and use thereof


This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode ha proteins having additional glycosylation sites, relative to the ha proteins encoded by the corresponding virulent parental viruses.
Merial Inc.


05/05/16
20160120967 

Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)


The modified s-lps and combinations thereof have high safety profile and provide low pyrogenicity and high immunogenicity. Developed on their basis vaccines and pharmaceutical compositions demonstrate anti-shock activity, high efficiency and specificity, broad-spectrum action and also good chemical-pharmaceutical parameters..

05/05/16
20160120799 

Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus


The present invention relates to microneedle vaccine formulations, as well as methods of use thereof to provide animals, including canines, protective immunity against infection and disease caused by rabies viruses. Once placed onto the skin of the animals, the microneedle formulations dissolve quickly into the surrounding skin, where the antigens then elicit in the animals high and protective levels of rabies virus neutralizing antibodies..
Merial, Inc.


04/28/16
20160115250 

Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof


This disclosure relates to synthetic oligosaccharide subunits of the pseudomonas exosaccharide psi and uses thereof, e.g., for epitope mapping of anti-psl antibodies, for identification of anti-psl antibodies, and for use as vaccines. In one aspect a synthetic oligosaccharide subunit of a pseudomonas aeruginosa psl oligosaccharide is provided, comprising the trisaccharide of formula i..
The University Of Georgia Research Foundation


04/28/16
20160114033 

Aluminum compounds for use in therapeutics and vaccines


The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition..
Valneva Austria Gmbh


04/28/16
20160114030 

Nucleic acid molecule encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same


Provided herein are nucleic acid sequences encoding hepatitis b virus (hbv) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents.
The Trustees Of The University Of Pennsylvania


04/28/16
20160114026 

Pan-lyssavirus vaccines against rabies


Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as mokola virus, lagos bat virus and/or west caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


04/28/16
20160114022 

Therapies, vaccines, and predictive methods for filoviruses including ebolavirus and marburg virus


The present invention provides therapies, vaccines, and predictive methods for filoviruses, including ebolaviruses and marburg viruses, and provides compounds for diagnosing, preventing, and treating outbreaks of filoviruses.. .

04/28/16
20160114021 

Novel surface exposed haemophilus influenza protein (protein e; pe)


The present invention relates to a surface exposed protein (protein e; pe), a virulence factor, which can be detected in haemophilus influenzae, having an amino acid sequence as described in seq id no 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pe(a)) or truncated variants thereof based on said surface exposed protein. Nucleic acid sequences, vaccines, plasmids and phages, non human hosts, recombinant nucleic acid sequences, fusion proteins and fusion products are also described.

04/28/16
20160114020 

Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax


The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of b. Anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines.
Altimmune Inc.


04/28/16
20160114018 

Imp-3 epitope peptides for th1 cells and vaccines containing the same


Isolated imp-3-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


04/28/16
20160114017 

Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines


Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant..
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


04/21/16
20160108371 

Recombinant vaccinia virus derived from kvac103 strain


Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain kvac103. The recombinant virus vector is obtained by inserting an exogenous gene into the kvac103 and may be used as a safe vaccine delivery vehicle in mammals.

04/21/16
20160108367 

Mdck-derived cell strain suspension-cultured in protein-free medium and proliferating virus using cell strain


The present invention relates to a novel mdck-derived cell line capable of being suspension-cultured in a protein-free medium and a method for proliferating a virus using the mdck-derived cell line to produce a vaccine. The novel mdck-derived cell line exhibits high and uniform productivity for various viruses, while causing less viral antigenic variations with low tumorigenicity, and thus can be useful in producing viruses used for vaccines..

04/21/16
20160106830 

Vaccines against hepatitis b virus


A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in seq id nos: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in seq id nos: to 4, wherein each peptide comprises at least one cd8+ t-cell epitope and/or at least one cd4+ t-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (pbmc) from at least one chronically infected hbv individual in an 10 in vitroassay.. .

04/21/16
20160106828 

Adaptation of attenuated infectious bronchitis virus (ibv) to embryonic kidney cells and vaccine thereby produced


Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (ibv). The methods typically include passing a heterogeneous attenuated population of ibv in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of ibv in embryonated chicken eggs (ece) in order to obtain passaged attenuated population of ibv.

04/21/16
20160106826 

Vaccines against pathogenic escherichia coli and methods of using the same


Provided herein are compositions and methods for vaccinating against infection with pathogenic escherichia coli (e. Coli).

04/14/16
20160103128 

Novel immunogenic proteins of leptospira


The invention provides novel immunogenic proteins liga and ligb from leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.. .

04/14/16
20160102291 

Dendritic cell compositions and methods


Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° c.-34° c. For a period of approximately 6 to 96 hours from the time they are isolated from a subject.

04/14/16
20160102143 

Modulating regulatory t cell activity via interleukin 35


Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.3153

4691

3 - 0 - 102